Multi-Drug Resistant Nephrotic Syndrome
8
6
6
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (8)
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
Blinatumomab for CNI-Resistant/Intolerant SRNS in Children